The company is using the funds to continue to advance its non-opioid pain drug candidate into clinical trials.
Led by James Segermark, President & CEO, InSitu Biologics is advancing a a new, opioid-free painkiller called AnestaGel.
In pre-clinical studies, AnestaGel has proven to be a fast acting and long lasting, non-opiate painkiller, targeted for use in post-operative regional pain management and is expected to be explored for use in numerous surgical applications.
The Securities and Exchange Commission (SEC) Qualified InSitu on July 17, 2018, to raise up to $10 million using Reg A+. Reg A+ allows private companies to raise up to $50 million from the general public over a 12 month period. The SEC qualified Form 1-A can be found here: https://www.sec.gov/Archives/edgar/data/1723443/000147793218002887/insitu_1a.htm
FinSMEs
04/12/2018